Introduction {#hox003s11}
============

Oocyte cryopreservation (OoC) practice is increasing in Europe and worldwide, and has been described as 'women\'s emancipation set in stone' ([@hox003C21]), especially since the advent of the more efficient vitrification technique ([@hox003C36]). It is of importance to cancer patients, or any woman whose ovarian reserve is endangered by a medical condition and/or its treatment. It can also be important to women as a possible backup method or 'insurance' to ameliorate their chances of conception when postponing pregnancy. Furthermore, since the American Society for Reproductive Medicine removed the 'experimental label' ([@hox003C35]) and the American Society of Clinical Oncology ([@hox003C26]) updated its guidelines with regard to both OoC and ovarian tissue cryopreservation (OtC), the practice has further grown worldwide.

A substantial number of oocytes are increasingly cryopreserved in Europe, but only a few countries collect specific detailed data for this purpose. The total number of ovarian tissue biopsies or ovaries cryopreserved in Europe is unknown, and it is difficult to accurately inform women about the efficiency of the method, more specifically used prior to cancer treatment in children or adolescents where stimulation for OoC is not possible.

The medical indications for OoC are both general and ART specific. General medical indications include mostly women whose cytotoxic cancer treatment threatens their ovarian reserve or whose medical pathology presents a similar danger. This is the case for severe endometriosis ([@hox003C37]), genetic disorders such as mosaic Turner\'s syndrome ([@hox003C34]), or severe Crohn\'s disease necessitating cytotoxic drugs. Such 'medical indications' for OoC avoid ethical debates about the nature of the embryo and its cryopreservation ([@hox003C14]; [@hox003C15]), or legal disputes about embryo transfer when a couple breaks up ([@hox003C18]). They may also present the advantage of avoiding the need for egg donation when the recovered patient wishes for a pregnancy at a later stage. Other medical but ART-specific indications accepted in current practice include emergency freezing in IVF when sperm is not available on the day of oocyte retrieval, prevention of ovarian hyperstimulation syndrome (OHSS) or accumulation of oocytes either in cases of poor responders or to increase their availability for PGD ([@hox003C1]). A recent indication is also being developed in transgender people, in case of female to male change ([@hox003C46]; [@hox003C11]). Furthermore, improved efficiency thanks to vitrification has led to the creation of donor egg banks which simplifies the logistics of egg donation and avoids the need to match donor\'s and recipient\'s cycles, and alleviates waiting lists ([@hox003C7]).

In contrast, the other indication, variously labelled as 'non-medical', 'social' or 'elective' because of age-related loss of oocytes has led to vigorous semantic debates. These debates include ethical issues, as respect of women\'s autonomy, as well as social concerns of equity ([@hox003C17]) and public funding. It is important to keep in mind that medicine must do as little harm as possible, and pregnancy at a later age involves more complications and costs. Indeed, the postponement of first pregnancy in the late last century and the beginning of this century is well documented ([@hox003C31]), as are the many socio-cultural reasons linked by scholars in social sciences to changes in the female gender roles with better access to contraception, and access to further education and career opportunities ([@hox003C4]). This is also described by women who are thinking of electively cryopreserving oocytes ([@hox003C38],[@hox003C39]), when they spend more time in education aiming at a fulfilling career, and voice concerns of not having yet met the appropriate future father of their wanted family. It appears however, that both women, whatever their level of education ([@hox003C27]), and professionals tend to underestimate age-related fertility decline ([@hox003C48]).

Vitrification and the possibility for women to 'put eggs on ice' efficiently have made many press headlines, especially in the non-medical context, but there are few specific national data, although collection has started or is planned in some countries. This uneven recording of information reinforces the need for large databases about collection and use of OoC, in order to assess whether OoC will prove to be a panacea or a delusion ([@hox003C25]). Indeed a recent review summarizing the history, techniques, indications and outcome of OoC stresses 'the real need to monitor what is being done, ... and the success rates achieved' ([@hox003C1]) and points out there is still a need to obtain wider quantitative and qualitative information.

With regard to OtC, the technique has been used both for children/adolescents ([@hox003C48]) and adults. In adults, there is as yet no consensus as to which approach (OoC or OtC) is optimal, although, with regard to the urgency of starting chemotherapy, timeliness is often the decisive factor. Whilst the first attempt at autotransplantation of frozen thawed ovarian tissue dates from 2001 ([@hox003C33]), and the first live birth was published in 2004 ([@hox003C13]), OtC nowadays allows a realistic chance of pregnancy after gonadotoxic therapy, by orthotopic or heterotopic retransplantation of ovarian tissue stored before cancer treatment.

The purpose of the present study was to improve the general knowledge of OoC and OtC rules and practice in Europe: first, to obtain information on legal or professional codes of practice, indications, and reimbursement of the treatment, and second to collect data on numbers of cycles performed and oocytes stored by indication and by country.

Materials and Methods {#hox003s12}
=====================

A collaboration between two ESHRE groups, the Special Interest Group for Socio Cultural Aspects of Infertility (SCAIF) and the European IVF Monitoring (EIM) was started in 2014, with three members of each group planning the study and its protocol, and designing a two part questionnaire (see [Supplementary Data](#sup1){ref-type="supplementary-material"}). In the first part, we asked whether OoC was submitted or not to a law or code of practice (COP), whether regulations concerned or not women\'s age, civil status, medical indications: serious disease (woman, child-adolescent), other medical indication (poor ovarian reserve, poor responders, OHSS risk, PGD/PGS) and egg donation. A specific question concerned OoC authorization for non-medical indications, and if it was reimbursed or not. In the second part, we also asked for both the number of cycles performed and oocytes retrieved in total and by main indications since 2010. All 'other' medical indications were grouped as a single item for simplicity. The survey was conducted during 2015, and at the end of 2015, data were also sought about OtC through a short second questionnaire (see [Supplementary Data](#sup1){ref-type="supplementary-material"}). The questionnaires were sent to all national coordinators of the EIM register in early 2015, and to members of the ESHRE committee of national representatives. Whenever possible, further information was sought, such as in the UK where more recent data were obtained through a Freedom of Information (FOI) request, which according to the [@hox003C20] compels public bodies to answer a question within 3 weeks.

All data were sent to ESHRE Central office. A descriptive analysis was performed after tabulation. Analysis comprised a description of national regulations (questionnaire part 1) and then a description of the practice reported by countries having filled out part 2. The number of cycles reported during the whole period was described per year, allowing for a trend estimation. However, several countries did not report data every year, either because OoC was not practiced, or not recorded between 2010 and 2012. Furthermore, the questionnaire was sent too early to get all data for the year 2014. Thus, the detailed description by indication was performed on the year 2013 where data were the most comprehensive.

Results {#hox003s13}
=======

Overall, amongst the 34 countries contributing to EIM, the Part 1 questionnaire was completed in 27 countries, whilst Part 2 of the OoC questionnaire was only completed in 17, and the OtC questionnaire in 12.

Regulatory background and funding {#hox003s13a}
---------------------------------

### Regulations {#hox003s13a_1}

The picture is far from homogeneous in Europe, and varies from strict legislation forbidding non-medical indications to allowing both medical and non-medical indications, mostly by not excluding the latter (Table [I](#hox003TB3){ref-type="table"}). In 12 countries, no specific regulation for OoC existed, while 14 countries rely on a law (of which 6 have a COP) and 1 (Romania) only on a COP. Many have a register for ART but, in 2015, there were two national registers where the number of OoC cycles was available, whilst four more are planned in the near future, such as in Denmark, Italy, and the Netherlands during 2016, or France (2017). With regard to the UK, aggregated data for 2013 were included in the most recent annual report ([@hox003C24], [www.hfea.gov.uk](www.hfea.gov.uk)), but there are no plans to present them more specifically according to indications in the near future. Table IRegulations, indications, and funding for OoC in 2015 for 27 European countries.CountrySpecific regulationART registerIndications for freezingFundingGeneralOoC^[\*](#hox003tfn4){ref-type="fn"}^Age (years)MedicalNon-medicalMedicalNon-medicalAustriaLawYesNoNoYesForbiddenNoNoBelarusNoNoNoNoYesNoNoNoBelgiumNoYesYes\<45NoNoYesNoBulgariaNoNoNoNoYesYesNoNoCzech RepublicNoYesNoNoNoNoYesNoDenmarkLawYes*2016*\<46YesNoYesNoEstoniaNoNoNoNoNoNoNoNoFinlandLawYesNoNoNoYesYesNoFranceLaw/COPYes*2017*18--42YesForbidden[\*\*](#hox003tfn5){ref-type="fn"}YesNoGermanyLaw/COPYesYes20--49YesYesNoNoGreeceNoNoNoNoNoNoNoNoHungaryLawYesNoNoYesNoNoNoItalyLawYes*2016*NoYesYesYesNoIrelandNoNoNoNoNoNoYesNoLithuaniaNoNoNoNoNoNoNoNoMaltaLaw/COPYesNo25--42YesForbiddenYesNoNetherlandsLaw/COPNo*2016*NoYesYesYesNoNorwayLawYesNoNoYesNoYesNoRomaniaCOPYesNoNoNoNoNoNoRussiaNoNoNoNoYesNoNoNoSlovakiaNoNoNoNoNoNoNoNoSloveniaLawNoNo\<45YesNoYesNoSpainLawYesNo\>18NoNoYesNoSwedenNoYesNoNoNoNoYesNoSwitzerlandLaw/COPYesNoNoNoNoNoNoUKLaw/COPYesNoNoNoNoYesNoUkraineNoNoNoNoYesYesNoNo[^2][^3][^4]

### Criteria and conditions for freezing {#hox003s13a_2}

Only seven countries specified a minimum or maximum age limit, applying to both medical and non-medical indications in Belgium (below 45 years), Denmark (\<46 years), Germany (20--49 years) and Spain (\>18 years), whilst in France (18--42 years), Malta (25--42 years) and Slovenia (\<45 years), it applies to medical indications only as storing for non-medical reasons is either not practiced or not allowed (Table [I](#hox003TB3){ref-type="table"}). Only three countries specifically forbid non-medical OoC, Austria, France (except for egg donors with no children, since spring 2016) and Malta. Most other countries practicing non-medical freezing do so in a context of the absence of specific law. Furthermore, the rules for non-medical freezing may depend on a professional society decision. In Denmark, cryopreserved oocytes may be kept initially for 5 years and the cryopreservation period is extendable for medical reasons; moreover, oocytes can be donated to research, but not for reproduction, with further written consent.

### Funding {#hox003s13a_3}

With regard to funding, OoC is free for medical reasons in 14 (just over half) responding countries, either through direct state funding or a compulsory insurance system such as in the Netherlands (Table [I](#hox003TB3){ref-type="table"}). Non-medical OoC is never funded by any state system. The UK allows cryopreservation for 10 years, renewable with further consent 'if there is a serious risk of permanent infertility' up to the age of 55 years, and is free in the National Health Service for medical reasons.

Number of cycles performed and oocytes retrieved for OoC during 2010--2014 {#hox003s13b}
--------------------------------------------------------------------------

In total, 34 753 OoC cycles were reported during the 5-year-period among 17 countries with available data, with a progressive annual increase, except in 2014 where the report was incomplete (Table [II](#hox003TB4){ref-type="table"}). During the period 2010--2013, this increase was partly due to an increase in seven countries, (Belgium, Czech Republic, France, Germany, Greece, UK and Ukraine) and new developments in five countries (Belarus, Finland, Hungary, Malta and Switzerland), whereas the numbers were fluctuating in four countries (Estonia, Italy, Slovenia and Spain). Data were too inconsistent to be presented for Romania. It also can be noticed that the greatest user of OoC was Spain, with fluctuating data during 2010--2013, followed by UK and France. In 2014, even with incomplete data available, there has been a significant increase in Spain, UK and Ukraine. Table IIOoC cycles in 17 participating countries during 5 years.Countries20102011201220132014^[\*\*](#hox003tfn7){ref-type="fn"}^BelarusNA0NA3NABelgium1049310386NACzech Rep68220344471202Estonia16048FinlandNANANA23NAFranceNANA451798NAGermany120130141235227Greece[\*](#hox003tfn6){ref-type="fn"}89103434Hungary[\*](#hox003tfn6){ref-type="fn"}NANA252Italy286554415477358Malta00NA4120RomaniaNANANANANASlovenia918141627SpainND5612645256206670SwitzerlandNANANA48NAUK3324585938101063Ukraine112791155265Total:178457083882391268876[^5][^6][^7]

Number of OoC cycles performed in 2013 according to indications {#hox003s13c}
---------------------------------------------------------------

OoC was performed in all countries who had data for 2013 (*n* = 17) (Table [III](#hox003TB5){ref-type="table"}). In six countries, including Finland, France and Spain, the total number of OoC cycles performed was not accompanied by the number of oocytes retrieved. The UK published specific data by indication for their annual report in 2011, but has since stopped. More recent data were thus obtained through a FOI request. Table IIIGeneral data on OoC practice in Europe, year 2013 (total 17 countries).CountriesTotal numbersNumbers per OoC indicationsTotal ART aspirationsOoC aspirationsOocytes numberOD cycles/oocytesSerious disease cycles/oocytesOther medical cycles/oocytesNon-medical cycles/oocytesBelarus2000370/00/03/70/0Belgium19 5903863750NANANA366/2698Czech Rep18 5744715799169/2178NA302/451NAEstonia18364310/00/02/232/8Finland486123NANANANANAFrance62 235798NANA324/NA474/NA0/0Germany56 0752351350NANANANAGreeceNA342032/1410/358/1057/33Hungary^[a](#hox003tfn9){ref-type="fn"}^3535536*0/0*NA4/27NAItaly50 17447736890/0152/1456296/199929/234Malta10041NA0/00/041/NANARomania2156NANA45/240NANANASlovenia3668162100/09/1357/750/0Spain54 1295620NA4853/NA262/19708/60497/3738Switzerland496448NANA41/NANA7/NAUK46 4218107042118/1099165/1366270/2462257/2115Ukraine12 7071551538136/13543/2116/1630/0Total: 17343 025912623 6555323/4885966/49831431/53721165/8826[^8][^9][^10]

A total of 9126 specific OoC cycles were performed in the 16 countries with available data, out of a total of 343 025 ART aspirations (or 2.7% of all aspirations), with Spain performing 61.6% of all. Indications were reported for 8885 cycles (97.4%). Overall, 59.9% OoC specific cycles were performed for egg donation, whilst the proportion of cycles performed for serious disease, other medical indications and non-medical reasons were respectively 10.9%, 16.1% and 13.1% of the total number of OoC cycles.

Number of oocytes retrieved {#hox003s13d}
---------------------------

The number of oocytes was very unevenly reported in 2013 by 14 countries (Table [III](#hox003TB5){ref-type="table"}). The total number (*n* = 23 655) was reported by 11 countries (9.1 per aspiration) and the number by indication by 13 countries, furthermore differing according to the four indications. For instance, only Greece and the UK provided the fullest data for all indications, whilst only 5 countries reported this number for oocyte donation (OD), 6 for serious disease, 10 for other medical indications and 6 for non-medical indication. Unfortunately, Spain, a major player in the field of OoC for OD started to record the number of oocytes retrieved in OD cycles only in 2014. Thus, in this restricted and uneven sample, the highest average yield of oocytes was found in case of OD (10.4; SD 2.3), followed by serious disease (8.3; 1.3), non-medical (7.6; 0.4) and 'other medical' ART indications (5.9; 3.3).

Use of cryopreserved oocytes {#hox003s13e}
----------------------------

These data were too poorly reported to be presented in a table. For medical indications, 13 countries reported 773 cycles, of which 10 included the number of thawed oocytes (*n* = 3823). With regard to non-medical OoC use, only four countries reported 53 cycles, of which three reported the use of 365 oocytes. Moreover, Spain reported medical and non-medical indications together.

Storage and use of ovarian tissue {#hox003s13f}
---------------------------------

While 24 questionnaires were returned, only 12 countries recorded storage of ovarian tissue. Data were unavailable in 7 countries and these techniques were not practiced in 5. By the end of 2014, Germany, France and Denmark had recorded the highest number of stored ovarian tissue samples between 2010 and 2014 (Table [IV](#hox003TB6){ref-type="table"}). With regard to OtC use, only 10 countries had data. During 2013, the year with most complete data, the total number of samples stored and samples used were, respectively, 1055 and 52. Table IVNumber of OtC and ovarian graft procedures in 12 countries in 2010--2014.CountryOvarian tissue cryopreservationOvarian tissue graft20132010--201420132010--2014Austria3314701Belgium103624823Denmark653461434Estonia838NA0Finland105704France27710961029[\*](#hox003tfn12){ref-type="fn"}Germany396149916[\*\*](#hox003tfn13){ref-type="fn"}69[\*\*](#hox003tfn13){ref-type="fn"}Italy98399111Netherlands135605[\*\*\*](#hox003tfn14){ref-type="fn"}Norway[\*](#hox003tfn12){ref-type="fn"}1310003Slovenia11400Switzerland389836Total1055447452185[^11][^12][^13]

Discussion {#hox003s14}
==========

Data quality {#hox003s14a}
------------

The quality of data is very variable according to countries. Indeed, whilst the EIM group has added a question concerning the use of cryopreserved oocytes in ART cycles ([@hox003C22]), only some countries have started recording data in professional national registers, mostly as summaries. Furthermore, until recently, this was mostly in the context of egg donation, such as in Spain, or of spare oocytes from ART cycles when the Italian law was restrictive and banned embryo freezing ([@hox003C6]). On the whole, we had good data for 15 out 17 countries on numbers of specific OoC cycles performed. After Spain, the UK, France, Italy, Czech Republic and Belgium are also major players in the field. Spain, however, performed more than 60% of all OoC cycles reported in 2013, and the next important player in the field, France, performed 8.7% of cycles.

However, data on the number of oocytes retrieved according to indications were incomplete. It is therefore impossible to speculate on the different yields of oocytes per cycle and per indication, although fuller data, especially from Spain in the case of OD, should enable this in the near future.

With regard to OtC, the major player is Germany with the highest number of biopsies and grafts of all reported, performed between 2010 and 2014, followed by France (in the period 2010--2013), but data were not complete or not available nationally in some countries such as the UK where the practice is patchy (Davies, personal communication, 2016).

What can be inferred from the data for OoC and OtC? {#hox003s14b}
---------------------------------------------------

Whilst the data are not full or exhaustive, this study is the first to present a set of OoC data for a large number of European countries. We collected 9126 OoC aspirations from 17 countries in 2013, representing around 2.3% of all ART aspirations, yielding a total number of 23655 oocytes cryopreserved. This activity has also been growing over the last 5 years.

The total number of OtC performed in 12 countries in 2013 can only be compared as a whole with the 9126 OoC cycles for the same year. Different countries emphasize the use of either method, but some groups, such as the network FertiProtekt in German-speaking countries (Germany, Austria, Switzerland) ([@hox003C19]) have elected to concentrate on OtC. This group, following the international Guidelines of the American Society of Clinical Oncology (ASCO), recommends that all women up to the age of 40 years who undergo gonadotoxic therapy should be counselled about fertility preserving techniques by specialized physicians ([@hox003C45]). Data collection in this network is now internet based and can summarize activities from more than 140 units of reproductive medicine, with a recent publication including the results of 95 orthotopic transplantations of ovarian tissue after cytotoxic treatment ([@hox003C44]). FertiProtekt represents a valuable model, together with the case of Denmark, which also performs a large number, especially taking into account the small size of this country population.

Reflections from the mosaic of policies {#hox003s14c}
---------------------------------------

Legislation, professional codes and access are more of a patchwork than uniform in Europe. In several countries, availability of OoC is only for the various medical reasons outlined, and in all countries public funding is reserved for such indications. It has been argued, however, that the margin between medical and non-medical indications may be blurred ([@hox003C16]), and it is necessary to further refine 'medical' indications, especially in the case of poor ovarian reserve, generally considered a disease before 40 years of age and not afterwards. It appears that until now the definition of 'non-medical', sometimes called 'social' is made by exclusion, an important distinction, as no country provides public funding for this. Worse, there is no general agreement for what constitutes a genuine medical indication, as exemplified by the case of a young woman who was refused state funding in the UK after chemotherapy for severe ulcerative colitis severely endangered her reproductive future ([@hox003C28]). The distinction between medical and non-medical indications is relevant to all countries, but access to the technique may be impeded by funding even if the law itself is open to all possibilities. For instance, in the UK, ART law has enabled access for single women and same sex couples since 1990, ([@hox003C23]) and all indications for OoC are allowed, but funding varies between regions even for medical reasons, making access subject to regional decisions. This disagrees with the National Institute for Clinical Excellence (NICE) recommendations of three cycles for all patients ([@hox003C32]). The Human Fertilisation and Embryology Authority register has full coverage of ART cycles nationally, but there are no separate national data on provisions in cancer patients as yet (Davies, 2016, personal communication). In France, access to ART is restricted to medical indications (infertility or serious risk of disease transmission) and has public funding nationally. However, a recent modification was passed in order to promote gamete donation because of an important lack of donors who were required to already have children ([@hox003C10]). This decree allows young women without children to give eggs but also implies that they have to be offered self-freezing of a number of oocytes according to the available number given to others ([@hox003C2]). This makes a new exception allowing a non-medical indication for OoC. Finally, some women are already travelling outside their own country for elective 'social' freezing, another form of cross-border reproductive care, in order to obtain this possible insurance on their reproductive future, as the practice may be illegal at home ([@hox003C50]), especially if there are no medical indications warranting state funding. This applies to French women going to Belgium (Stoop, personal communication, [@hox003C42]), Spain or the UK, and is another example of women exercising their autonomy in reproductive choices or out of necessity ([@hox003C16]).

The importance of terminology {#hox003s14d}
-----------------------------

The terminology for non-medical OoC has been discussed widely. Some authors proposed the terms 'social' ([@hox003C29]), or 'elective cryopreservation to defer childbearing' ([@hox003C35]), preferring to point out the inevitable biology of 'age-related fertility decline' for women. In this aspect, the proposition of freezing for 'anticipated gamete exhaustion' ([@hox003C41]) stresses the biological and preventative nature of this deliberate step taken by women against the ills of nature ([@hox003C40]). Whatever the terminology, and in both 'Oocyte Cryopreservation for age related fertility loss' ([@hox003C12]; [@hox003C16]) and for medical reasons, accurate data are relevant to women, practitioners and policy-makers alike.

Conclusion {#hox003s15}
==========

This study is the first presenting the conditions for storage and use, and available data for OoC cycles and number of cryopreserved oocytes, as well as OtC in most European countries, and means to be a trigger and motivator to continue collection of these data prospectively. It was found that, for the time being at least, equitable access to OoC for women with medical indications is patchy in Europe, and that there is no funding for age-related non-medical reasons. Indeed in our data, the main reason for storage was for use in egg donation, with similar numbers of cycles for medical indications, ART cycles and non-medical reasons. The practice of non-medical OoC still raises a lot of ethical and social--cultural issues, including access ([@hox003C30]), public policy for child care enabling women to have children when their fertility is optimal, and education of young women (and men) about the natural decline of ovarian reserve with age ([@hox003C40]). Information must also point out the lower ART efficiency after the age of 35 years ([@hox003C8]). The development of non-medical indications requires forward thinking from all stakeholders, such as healthy women thinking about what has been portrayed as a possible insurance of their reproductive future, but does not carry with it any certainty for success. Accurate information is paramount, whether for patients as well as patients' organizations and policy-makers. A website with information can be a useful tool ([@hox003C3]). Most importantly, the choice made by all stakeholders should be backed up by verifiable information supported by data from professionals ([@hox003C5]), and professional societies.

ESHRE could be one of the major players in this process, with the possibility to inform all stakeholders about the reality of the chances of having a child born after OoC (and/or OtC), and a better appraisal of efficiency, as OoC (and OtC) cannot be more than a partial insurance against age-related fertility decline, varying in efficiency with indications and age. With an increase of reliable data, ART professionals should hopefully be able to better assess objectively the efficiency of this method of fertility preservation so that women and funding bodies may make an informed decision about using it as a back-up to natural fertility when circumstances demand it.
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